Suraksha Diagnostic Limited (SURAKSHA) Fair Value & Analysis
Healthcare · IN · Market cap ₹14.2B
Fair value as of: Jul 3, 2026
From 24 valuation models · updated today
Share price −6.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹227.95 – ₹327.90 · fair‑value band ₹92.70 – ₹184.20 · the ₹273.55 price screens above the ₹134.26 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Suraksha Diagnostic Limited (SURAKSHA) currently trades at ₹273.55, while our model-based Fair Value estimate is ₹134.26 — implying the stock looks roughly 50.9% overvalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Suraksha Diagnostic Limited generated revenue of ₹3.1B at a net margin of 10.4%. Revenue grew 31.2% year over year. It earns a return on equity of 13.8%. Net debt stands at ₹1.0B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Suraksha Diagnostic Limited reported revenue of ₹3.1B in FY2026 versus ₹2.2B in FY2022, a compound +8.6%/yr. Reported net income was ₹322M in FY2026, compounding +11.5%/yr from FY2022.
Is SURAKSHA fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Suraksha Diagnostic Limited (SURAKSHA) undervalued?
What is the fair value of SURAKSHA?
What is the quality score of SURAKSHA?
What is the revenue of Suraksha Diagnostic Limited (SURAKSHA)?
What is the net profit margin of SURAKSHA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.